A detailed history of Hellman Jordan Management CO Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hellman Jordan Management CO Inc holds 5,349 shares of VRTX stock, worth $2.67 Million. This represents 2.62% of its overall portfolio holdings.

Number of Shares
5,349
Previous 4,641 15.26%
Holding current value
$2.67 Million
Previous $1.34 Million 14.96%
% of portfolio
2.62%
Previous 2.33%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 20, 2023

BUY
$285.76 - $321.48 $202,318 - $227,607
708 Added 15.26%
5,349 $1.55 Million
Q3 2022

Oct 13, 2022

SELL
$273.83 - $305.53 $550,672 - $614,420
-2,011 Reduced 30.23%
4,641 $1.34 Million
Q2 2022

Sep 27, 2022

BUY
$234.96 - $292.55 $419,638 - $522,494
1,786 Added 36.7%
6,652 $1.87 Million
Q1 2022

Jun 16, 2022

SELL
$221.42 - $260.97 $646,767 - $762,293
-2,921 Reduced 37.51%
4,866 $1.27 Million
Q4 2021

Jan 26, 2022

SELL
$177.01 - $223.45 $544,128 - $686,885
-3,074 Reduced 28.3%
7,787 $1.71 Million
Q3 2021

Oct 26, 2021

BUY
$181.39 - $202.99 $606,930 - $679,204
3,346 Added 44.52%
10,861 $1.97 Million
Q2 2021

Jul 21, 2021

BUY
$187.49 - $221.1 $2,062 - $2,432
11 Added 0.15%
7,515 $1.52 Million
Q1 2021

May 06, 2021

BUY
$207.02 - $241.31 $1.36 Million - $1.59 Million
6,580 Added 712.12%
7,504 $1.61 Million
Q4 2020

Jan 29, 2021

BUY
$207.01 - $276.09 $14,490 - $19,326
70 Added 8.2%
924 $218,000
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $4,601 - $5,455
18 Added 2.15%
854 $232,000
Q2 2020

Jul 21, 2020

SELL
$225.48 - $295.8 $1,352 - $1,774
-6 Reduced 0.71%
836 $243,000
Q1 2020

May 28, 2020

BUY
$199.77 - $247.81 $168,206 - $208,656
842 New
842 $200,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $128B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hellman Jordan Management CO Inc Portfolio

Follow Hellman Jordan Management CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hellman Jordan Management CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Hellman Jordan Management CO Inc with notifications on news.